Since SGLT-2 is expressed exclusively in kidney thus its inhibition act as a therapeutic target in T2DM without risk of hypoglycemia since it increases renal excretion of glucose without influencing insulin secretion (Edward and Robert, 2010[24]). This evidence concerns the gene INS and Hypoglycemia.